Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer

Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer

Objective: In the phase II ALTER-1202 (NCT03059797) trial, anlotinib significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced small-cell lung cancer (SCLC) who underwent at least 2 previous chemotherapy cycles, when compared with a placebo group. To...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Cuicui Zhang, Jing Wang, Xinyue Wang, Zhaoting Meng, Ying Cheng, Kai Li
Formatua: Artikulua
Hizkuntza:English
Argitaratua: China Anti-Cancer Association 2022-08-01
Saila:Cancer Biology & Medicine
Gaiak:
small-cell lung cancer
anlotinib
predictive factors
pfs
os
Sarrera elektronikoa:https://www.cancerbiomed.org/content/19/8/1249

Internet

https://www.cancerbiomed.org/content/19/8/1249

Antzeko izenburuak